Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects
Retrieved on:
Tuesday, July 18, 2023
Seniors, Biotechnology, Pharmaceutical, Optical, General Health, Health, Consumer, Clinical Trials, Glaucoma, Abstract, ARVO, Li Ka Shing Faculty of Medicine, NR, Eye, Control, NAD, UCL Institute of Ophthalmology, Research, ChromaDex, Trial of the century, School of Clinical Medicine, University of Cambridge, Medicine, Moorfields Eye Hospital, Patient, Peripheral vision, Randomness, School, Investigative Ophthalmology & Visual Science, Optic nerve, Association for Research in Vision and Ophthalmology, Regulatory affairs, Medical device, Medical imaging, Ophthalmology
Together, the promising results from these abstracts suggest that glaucoma patients have lower cellular NAD+ levels and thus replenishing NAD+ levels with a precursor, such as nicotinamide riboside (NR), may be a potential therapeutic strategy.
Key Points:
- Together, the promising results from these abstracts suggest that glaucoma patients have lower cellular NAD+ levels and thus replenishing NAD+ levels with a precursor, such as nicotinamide riboside (NR), may be a potential therapeutic strategy.
- Dr. Garway-Heath’s abstract titled “ Primary open angle glaucoma patients have lower systemic mitochondrial function, associated with lower systemic nicotinamide adenine dinucleotide (NAD) levels, compared to Controls ” observed significantly lower cellular NAD+ levels and impaired mitochondrial function in patients with primary open-angle glaucoma (POAG).
- Further, higher NAD+ levels were strongly associated with higher mitochondrial function parameters, suggesting increased NAD+ levels are associated with improved energy production and cellular activity.
- POAG is a condition where pressure builds inside the eye, causing damage to the optic nerve and gradual vision loss.